Interchangeable Biologics Clarity Act

Hozzl · 2022-12-29T16:48:34Z

Explore the details of Senate Bill 4303 Interchangeable Biologics Clarity Act currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

12/29/2022, 4:48 PM

Congressional Summary of S 4303

Interchangeable Biologics Clarity Act

This bill provides a statutory definition for first interchangeable biosimilar biological product and makes other technical changes with respect to the provisions that establish the corresponding periods of market exclusivity.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 4303

Bill S 4303 is currently in the status of Bill Introduced since May 25, 2022. Bill S 4303 was introduced during Congress 117 and was introduced to the Senate on May 25, 2022. Bill S 4303's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2709-2710) as of May 25, 2022

Bipartisan Support of Bill S 4303

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 4303

Primary Policy Focus

Health

Alternate Title(s) of Bill S 4303

Interchangeable Biologics Clarity ActInterchangeable Biologics Clarity ActA bill to provide for a period of exclusivity for first interchangeable biological products.

Start holding our government accountable!